Intragenic hypomethylation of DNMT3A in patients with myelodysplastic syndrome

Clin Chem Lab Med. 2018 Feb 23;56(3):485-491. doi: 10.1515/cclm-2016-0142.

Abstract

Background: DNMT3A is a DNA methyltransferase that acts in de novo methylation. Aberrant expression of DNMT3A has been reported in several human diseases, including myelodysplastic syndrome (MDS). However, the pattern of DNMT3A methylation remains unknown in MDS.

Methods: The present study was aimed to investigate the methylation status of DNMT3A intragenic differentially methylated region 2 (DMR2) using real-time quantitative methylation-specific PCR and analyze its clinical significance in MDS.

Results: Aberrant hypomethylation of DNMT3A was found in 57% (51/90) MDS cases. There were no significant differences in age, sex, white blood cell counts, platelet counts, hemoglobin counts and World Health Organization, International Prognostic Scoring System and karyotype classifications between DNMT3A hypomethylated and DNMT3A hypermethylated groups. However, the patients with DNMT3A hypomethylation had shorter overall survival time than those without DNMT3A hypomethylation (11 months vs. 36 months, p=0.033). Multivariate analysis confirmed the independent adverse impact of DNMT3A hypomethylation in MDS.

Conclusions: Our data suggest that DNMT3A DMR2 hypomethylation may be a negative prognostic hallmark in MDS.

Keywords: DNMT3A; hypomethylation; myelodysplastic syndrome.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • DNA (Cytosine-5-)-Methyltransferases / genetics*
  • DNA Methylation / genetics*
  • DNA Methyltransferase 3A
  • Female
  • Humans
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes / genetics*
  • Real-Time Polymerase Chain Reaction
  • Young Adult

Substances

  • DNMT3A protein, human
  • DNA (Cytosine-5-)-Methyltransferases
  • DNA Methyltransferase 3A